Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up

Wang,Xiaohua; Yin,Xiaoguang; Sun,Wei; Bai,Jin; Shen,Yawen; Ao,Qiang; Gu,Yongquan; Liu,Ying

doi:10.3892/etm.2017.4229

Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up

Authors:
- Xiaohua Wang
- Xiaoguang Yin
- Wei Sun
- Jin Bai
- Yawen Shen
- Qiang Ao
- Yongquan Gu
- Ying Liu
View Affiliations

Affiliations: Department of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China, Jilin Tuhua Bioengineering Company Ltd., Siping, Jilin 136000, P.R. China, Department of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, P.R. China
Published online on: March 14, 2017 https://doi.org/10.3892/etm.2017.4229
Pages: 2255-2258
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5x107 to 1x108. Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immunosuppressive drugs were used post‑first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP.

View Figures

View References

1	Berchtold P and McMillan R: Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood. 74:2309–2317. 1989.PubMed/NCBI
2	Imbach P: Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly. 142:w135932012.PubMed/NCBI
3	McMillan R and Durette C: Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 104:956–960. 2004. View Article : Google Scholar : PubMed/NCBI
4	Portielje JE, Westendorp RG, Kluin-Nelemans HC and Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 97:2549–2554. 2001. View Article : Google Scholar : PubMed/NCBI
5	Saeidi S, Jaseb K, Asnafi AA, Rahim F, Pourmotahari F, Mardaniyan S, Yousefi H, Alghasi A, Shahjahani M and Saki N: Immune thrombocytopenic purpura in children and adults: a comparative retrospective study in IRAN. Int J Hematol Oncol Stem Cell Res. 8:30–36. 2014.PubMed/NCBI
6	Qu Z, Guo S, Fang G, Cui Z and Liu Y: AKT pathway affects bone regeneration in nonunion treated with umbilical cord-derived mesenchymal stem cells. Cell Biochem Biophys. 71:1543–1551. 2015. View Article : Google Scholar : PubMed/NCBI
7	Qu Z, Guo L, Fang G, Cui Z, Guo S and Liu Y: Biological characteristics and effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) grafting with blood plasma on bone regeneration in rats. Cell Biochem Biophys. 63:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
8	Qu Z, Fang G, Cui Z and Liu Y: Cell therapy for bone nonunion: a retrospective study. Minerva Med. 106:315–321. 2015.PubMed/NCBI
9	Fang B, Mai L, Li N and Song Y: Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev. 21:497–502. 2012. View Article : Google Scholar : PubMed/NCBI
10	Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113:2386–2393. 2009. View Article : Google Scholar : PubMed/NCBI
11	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI
12	Pérez-Simón JA, Tabera S, Sarasquete ME, Díez-Campelo M, Canchado J, Sánchez-Abarca LI, Blanco B, Alberca I, Herrero-Sánchez C, Cañizo C, et al: Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy. 11:698–705. 2009. View Article : Google Scholar : PubMed/NCBI
13	Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, Bussel J and Yazdanbakhsh K: Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 120:3318–3325. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cines DB, Bussel JB, Liebman HA and Prak Luning ET: The ITP syndrome: pathogenic and clinical diversity. Blood. 113:6511–6521. 2009. View Article : Google Scholar : PubMed/NCBI